Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Biology Company Intrexon Raises $150M in Series F Preferred Investment Round

NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon said late Wednesday that it has closed a Series F preferred investment round that raised $150 million.

Proceeds from the financing round will be used for working capital to establish additional channel collaborations in the firm's core sectors, including healthcare, food, energy, and environment, it said, adding that funding will also be used for further development of its technology platforms and expansion of its sales and marketing and R&D efforts.

New investors accounted for the majority of funding in the round. Current investors, including affiliates of Intrexon Chairman and CEO Randal Kirk, as well as Third Security, also participated.

In total, the Germantown, Md.-based firm has raised $509 million, it said. About two years ago, it raised $100 million in a Series E round, and in January 2010 it raised $25 million.

"The Intrexon team is committed to delivering results for all of our collaborations," Kirk said in a statement. "With our proprietary technology platforms, we are helping our collaborators discover, design, develop, and ultimately bring to market genetically enhanced products that hold remarkable promise."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.